VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 78 filers reported holding VAXCYTE INC in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,724 | -41.8% | 53,434 | -43.0% | 0.00% | -33.3% |
| Q2 2023 | $4,678 | +161.5% | 93,677 | +96.2% | 0.01% | +200.0% |
| Q1 2023 | $1,789 | -32.4% | 47,744 | -13.4% | 0.00% | -50.0% |
| Q4 2022 | $2,645 | -99.7% | 55,152 | +49.6% | 0.00% | +300.0% |
| Q3 2022 | $885,000 | +10.8% | 36,860 | +0.4% | 0.00% | 0.0% |
| Q2 2022 | $799,000 | +8.0% | 36,705 | +19.7% | 0.00% | 0.0% |
| Q1 2022 | $740,000 | +8.7% | 30,656 | +7.1% | 0.00% | 0.0% |
| Q4 2021 | $681,000 | -6.6% | 28,629 | -0.4% | 0.00% | 0.0% |
| Q3 2021 | $729,000 | -5.7% | 28,734 | -16.4% | 0.00% | 0.0% |
| Q2 2021 | $773,000 | +85.4% | 34,352 | +62.8% | 0.00% | – |
| Q1 2021 | $417,000 | -4.8% | 21,100 | +27.9% | 0.00% | – |
| Q4 2020 | $438,000 | -46.3% | 16,500 | 0.0% | 0.00% | -100.0% |
| Q3 2020 | $815,000 | – | 16,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 4,168,718 | $90,711,000 | 29.04% |
| Medicxi Ventures Management (Jersey) Ltd | 3,774,956 | $82,142,000 | 17.06% |
| Pivotal bioVenture Partners Investment Advisor LLC | 832,166 | $18,108,000 | 9.12% |
| GREAT POINT PARTNERS LLC | 985,153 | $21,437,000 | 5.14% |
| Kynam Capital Management, LP | 723,781 | $15,749,000 | 4.02% |
| Ghost Tree Capital, LLC | 325,000 | $7,072,000 | 3.68% |
| Frazier Life Sciences Management, L.P. | 1,787,405 | $38,894,000 | 3.67% |
| RA Capital Management | 4,581,203 | $99,687,000 | 2.66% |
| Opaleye Management Inc. | 190,000 | $4,134,000 | 1.86% |
| Soleus Capital Management, L.P. | 370,650 | $8,065,000 | 1.26% |